10-Nov-2025 6:30 AM CST - Business Wire Organon Reports Results for the Third Quarter Ended September 30, 2025 Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. I am humbled to be working alongside our talented team during this pivotal time for Organon, said Joe Morrissey, Organons Interim Chief Executive Officer. We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to
9-Oct-2024 6:30 AM CST - Business Wire Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 Organon (NYSE: OGN), a global healthcare company with a focus on womens health, will release its third quarter 2024 financial results on October 31, 2024, prior to the companys webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record $51 million of milestone expense in the third quarter of 2024, representing an impact of approximately $0.16 to both GAAP and non-GAAP earnings per share. O
10-Nov-2025 6:30 AM CST - Business Wire Organon Reports Results for the Third Quarter Ended September 30, 2025 Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. I am humbled to be working alongside our talented team during this pivotal time for Organon, said Joe Morrissey, Organons Interim Chief Executive Officer. We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to
9-Oct-2024 6:30 AM CST - Business Wire Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 Organon (NYSE: OGN), a global healthcare company with a focus on womens health, will release its third quarter 2024 financial results on October 31, 2024, prior to the companys webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record $51 million of milestone expense in the third quarter of 2024, representing an impact of approximately $0.16 to both GAAP and non-GAAP earnings per share. O
